RxDoctor Payments DataLook up a doctor →

Robert Healy, MD

Neurology · Florence, SCNPI 1164400123

Payments from drug & device makers

$23,820in general payments, 2019–2025

Across 1,256 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • Novartis$2K
  • Biogen$1K
  • Sanofi$1K
  • EMD Serono, Inc.$1K
  • Acadia Pharmaceuticals Inc$1K
  • plus $14K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.163$3,164
Novartis95$1,777
Biogen82$1,451
Sanofi62$1,348
EMD Serono, Inc.56$1,142
Acadia Pharmaceuticals Inc49$1,036
AstraZeneca(2 entities)48$962
SK Life Science, Inc.40$919
Teva Pharmaceuticals USA, Inc.45$728
Eisai Inc.43$678
Supernus Pharmaceuticals, Inc.32$643
MDD US Operations, LLC38$635
AbbVie(2 entities)44$602
Pfizer34$563
Mallinckrodt Hospital Products Inc.26$544
Neurocrine Biosciences, Inc.27$536
Bristol Myers Squibb30$512
Amgen(2 entities)23$487
Sunovion Pharmaceuticals Inc.37$481
Argenx US, Inc.19$457
Alnylam Pharmaceuticals Inc.17$335
Johnson & Johnson(2 entities)14$327
Genentech USA, Inc.15$295
Upsher-smith Laboratories LLC19$283
Akcea Therapeutics, Inc.7$280
Catalyst Pharmaceuticals, Inc.12$273
Jazz Pharmaceuticals Inc.12$244
Lundbeck LLC10$185
Biohaven Pharmaceuticals, Inc.5$182
Acorda Therapeutics, Inc9$174
Neurelis, Inc.11$174
Takeda Pharmaceuticals U.S.A., Inc.7$169
Adamas Pharmaceuticals, Inc.10$167
TG Therapeutics, Inc.7$166
Biohaven Pharmaceutical Holding Company Ltd.9$163
ANI Pharmaceuticals, Inc.6$156
Aquestive Therapeutics, Inc.9$155
Banner Life Sciences, LLC5$131
Vanda Pharmaceuticals Inc.6$128
Otsuka America Pharmaceutical, Inc.5$127
Mallinckrodt Enterprises LLC11$120
Tanabe Pharma America, Inc.6$91
Lilly USA, LLC5$79
Sumitomo Pharma America, Inc.4$73
E.r. Squibb & Sons, L.L.C.3$66
Greenwich Biosciences, Inc.4$63
Currax Pharmaceuticals LLC5$58
Avanir Pharmaceuticals, Inc.3$51
Kyowa Kirin, Inc.4$50
Assertio Therapeutics, Inc.4$50
Xeris Pharmaceuticals, Inc.2$47
Livanova USA, Inc.2$43
Grifols USA, LLC3$39
Avion Pharmaceuticals2$33
Zogenix Inc.2$31
Idorsia Pharmaceuticals US Inc2$29
Corium, LLC1$26
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$25
Impel Pharmaceuticals Inc.1$21
Merz Pharmaceuticals, LLC1$19

How this compares

$23,820 in reported general payments places this provider in the 80th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina →

Medicare billing

Part B allowed, 2024
$447,000
Medicare patients
731
Services billed
3,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Florence

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →